{"id":"biological-vaccine-vla1553","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated whole chikungunya virus particles that trigger both humoral (antibody) and cell-mediated immune responses. By exposing the immune system to non-infectious viral antigen, it primes protective immunity without causing active infection, reducing the risk of symptomatic chikungunya disease upon natural exposure.","oneSentence":"VLA1553 is an inactivated chikungunya virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against chikungunya virus infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:43:15.206Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of chikungunya virus infection in at-risk populations and travelers"}]},"trialDetails":[{"nctId":"NCT04786444","phase":"PHASE3","title":"Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2021-02-22","conditions":"Chikungunya Virus Infection","enrollment":409}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Biological Vaccine VLA1553","genericName":"Biological Vaccine VLA1553","companyName":"Valneva Austria GmbH","companyId":"valneva-austria-gmbh","modality":"Biologic","firstApprovalDate":"","aiSummary":"VLA1553 is an inactivated chikungunya virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against chikungunya virus infection. Used for Prevention of chikungunya virus infection in at-risk populations and travelers.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}